牛熊異動 | 中國財險認購證漲超50%!
港股中國財險午後加速拉昇,截至發稿,中國財險漲近6%,報6.48港元,中險麥銀一四購A漲逾50%。
【通過日內融買入1手中國財險,僅需佔用本金1300港元】
近日,銀保監會披露的1月份保費數據顯示,1月份保險業呈現強勁復甦態勢,行業原保費收入同比增長11.2%。其中,佔行業保費87%的人身險業務收入同比增長13.8%。引人注意的是,1月份有兩大險種保費收入增速較快。一是健康險保費收入達1206億元,同比增長28.1%;二是投連險獨立賬戶新增交費達134億元,同比大幅增長222.8%。究其原因,健康險增速一方面受到疫情催化,另一方面與疫情控制後各行業回暖有關;投連險保費收入大增,則受益於去年以來資本市場的較好表現。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.